Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBridge Biosciences (NBP) Cash & Current Investments (2018 - 2022)

NovaBridge Biosciences (NBP) has disclosed Cash & Current Investments for 5 consecutive years, with $485.0 million as the latest value for Q4 2022.

  • Quarterly Cash & Current Investments fell 27.5% to $485.0 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $485.0 million through Dec 2022, down 27.5% year-over-year, with the annual reading at $485.0 million for FY2022, 27.5% down from the prior year.
  • Cash & Current Investments for Q4 2022 was $485.0 million at NovaBridge Biosciences, down from $668.9 million in the prior quarter.
  • The five-year high for Cash & Current Investments was $722.8 million in Q4 2020, with the low at $169.3 million in Q4 2019.
  • Average Cash & Current Investments over 5 years is $457.8 million, with a median of $485.0 million recorded in 2022.
  • The sharpest move saw Cash & Current Investments plummeted 30.36% in 2019, then skyrocketed 326.94% in 2020.
  • Over 5 years, Cash & Current Investments stood at $243.1 million in 2018, then tumbled by 30.36% to $169.3 million in 2019, then soared by 326.94% to $722.8 million in 2020, then fell by 7.46% to $668.9 million in 2021, then decreased by 27.5% to $485.0 million in 2022.
  • According to Business Quant data, Cash & Current Investments over the past three periods came in at $485.0 million, $668.9 million, and $722.8 million for Q4 2022, Q4 2021, and Q4 2020 respectively.